WuXi PharmaTech enters into supply agreement with Pharmacyclics


WuXi PharmaTech (WX) announced that its wholly owned subsidiary Shanghai SynTheAll Pharmaceutical, has entered into a supply arrangement with Pharmacyclics (PCYC). This follows a successful multiple-year development and clinical manufacturing partnership that supported Pharmacyclics with the expedited New Drug Application submission and final approval by the FDA. After an expedited review by the FDA, Imbruvica received approval on November 13 for treatment of patients with mantle cell lymphoma who have received at least one prior therapy. This indication is based on overall response rate. An improvement in survival or disease-related symptoms has not been established.

View Comments (0)